Prognosis of subglottic carcinoma: Is it really worse?

larynx prognosis squamous cell carcinoma subglottic cancer therapy

Journal

Head & neck
ISSN: 1097-0347
Titre abrégé: Head Neck
Pays: United States
ID NLM: 8902541

Informations de publication

Date de publication:
02 2019
Historique:
received: 27 05 2017
revised: 26 10 2017
accepted: 14 02 2018
pubmed: 28 6 2018
medline: 10 9 2020
entrez: 28 6 2018
Statut: ppublish

Résumé

It is traditionally accepted that subglottic carcinoma has a worse prognosis than tumors arising in other subsites of the larynx, owing to its tendency to present in advanced stages, with a high incidence of cartilage invasion and extralaryngeal spread. The incidence of subglottic carcinoma varies among series, mainly because there is no uniform definition of the upper boundary of the subglottis. The extent of the tumor may be difficult to define because subglottic carcinoma may spread through the submucosa without visible mucosal changes. There is also a rich lymphatic network in the subglottis draining to the prelaryngeal and paratracheal lymph nodes, which are usually not involved by cancers arising in other laryngeal subsites. Current literature data indicates that early-stage subglottic carcinoma can be treated using radiotherapy or chemoradiotherapy with high locoregional control and survival rates. In advanced stage subglottic carcinoma, combination of surgery followed by radiotherapy or chemoradiotherapy resulted in comparable outcomes, as in advanced carcinomas from the rest of the larynx. Stage for stage, it is likely that the prognosis for subglottic carcinoma and of glottic and supraglottic cancers is similar.

Identifiants

pubmed: 29947111
doi: 10.1002/hed.25172
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

511-521

Informations de copyright

© 2018 Wiley Periodicals, Inc.

Auteurs

Hakan Coskun (H)

Department of Otolaryngology - Head and Neck Surgery, Uludag University School of Medicine, Bursa, Turkey.

William M Mendenhall (WM)

Department of Radiation Oncology, University of Florida, Gainesville, Florida.

Alessandra Rinaldo (A)

University of Udine School of Medicine, Udine, Italy.

Juan P Rodrigo (JP)

Department of Otolaryngology, Hospital Universitario Central de Asturias, IUOPA, University of Oviedo, Centro de Investigación Biomédica en Red de Cancer (CIBERONC), Oviedo, Spain.

Carlos Suárez (C)

Instituto de Investigación Sanitaria del Principado de Asturias and Centro de Investigación Biomédica en Red de Cancer (CIBERONC), ISCIII, Oviedo, Spain.
Instituto Universitario de Oncología del Principado de Asturias, University of Oviedo, Oviedo, Spain.

Primož Strojan (P)

Department of Radiation Oncology, Institute of Oncology, Ljubljana, Slovenia.

Fernando López (F)

Department of Otolaryngology, Hospital Universitario Central de Asturias, IUOPA, University of Oviedo, Centro de Investigación Biomédica en Red de Cancer (CIBERONC), Oviedo, Spain.
Instituto de Investigación Sanitaria del Principado de Asturias and Centro de Investigación Biomédica en Red de Cancer (CIBERONC), ISCIII, Oviedo, Spain.
Instituto Universitario de Oncología del Principado de Asturias, University of Oviedo, Oviedo, Spain.

Vanni Mondin (V)

University of Udine School of Medicine, Udine, Italy.

Nabil F Saba (NF)

Department of Hematology and Medical Oncology, The Winship Cancer Institute of Emory University, Atlanta, Georgia.

Ashok R Shaha (AR)

Head and Neck Service, Memorial Sloan Kettering Cancer Center, New York, New York.

Robert Smee (R)

Department of Radiation Oncology, The Prince of Wales Cancer Centre, Sydney, New South Wales, Australia.

Robert P Takes (RP)

Department of Otolaryngology - Head and Neck Surgery, Radboud University Medical Center, Nijmegen, The Netherlands.

Alfio Ferlito (A)

Coordinator of the International Head and Neck Scientific Group.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH